WO2011106650A3 - Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease - Google Patents

Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease Download PDF

Info

Publication number
WO2011106650A3
WO2011106650A3 PCT/US2011/026251 US2011026251W WO2011106650A3 WO 2011106650 A3 WO2011106650 A3 WO 2011106650A3 US 2011026251 W US2011026251 W US 2011026251W WO 2011106650 A3 WO2011106650 A3 WO 2011106650A3
Authority
WO
WIPO (PCT)
Prior art keywords
mdm2
mdm4
antagonists
novel
proliferative disease
Prior art date
Application number
PCT/US2011/026251
Other languages
French (fr)
Other versions
WO2011106650A2 (en
Inventor
Alexander Doemling
Tad Holak
Original Assignee
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of WO2011106650A2 publication Critical patent/WO2011106650A2/en
Publication of WO2011106650A3 publication Critical patent/WO2011106650A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

High-resolution structural information delineates key interactions between MDM2 or MDM4 and heterocyclic compounds that bind to these proteins. These compounds are potent agonists of the p53-MDM2/p53-MDM4 complex.
PCT/US2011/026251 2010-02-27 2011-02-25 Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease WO2011106650A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30892510P 2010-02-27 2010-02-27
US61/308,925 2010-02-27

Publications (2)

Publication Number Publication Date
WO2011106650A2 WO2011106650A2 (en) 2011-09-01
WO2011106650A3 true WO2011106650A3 (en) 2012-01-19

Family

ID=44507586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/026251 WO2011106650A2 (en) 2010-02-27 2011-02-25 Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease

Country Status (1)

Country Link
WO (1) WO2011106650A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
CA2780547C (en) 2009-11-12 2015-02-03 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
SI2603600T1 (en) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EA201390682A1 (en) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган SPIROOXINDAL ANTAGONISTS MDM2
JP2014513699A (en) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Spiro-oxindole MDM2 antagonist
TWI643868B (en) 2011-10-18 2018-12-11 艾利倫治療公司 Peptidomimetic macrocycles
KR102112373B1 (en) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN103497164B (en) * 2013-09-23 2015-12-23 西安近代化学研究所 A kind of anthracene derivant and preparation method thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US9809539B2 (en) * 2015-03-03 2017-11-07 Shuttle Pharmaceuticals, Llc Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MX2017011834A (en) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
JP2018528217A (en) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycles as modulators of MCL-1
EP3371173A4 (en) * 2015-11-02 2019-06-19 Carmel-Haifa University Economic Corporation Ltd. Apoptosis related protein in the tgf-beta signaling pathway (arts) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
IT201700041723A1 (en) 2017-04-14 2018-10-14 Italfarmaco Spa New HDAC6 selective inhibitors
CA3087565A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293319A1 (en) * 2005-06-24 2006-12-28 Kim-Chun Luk Oxindole derivatives
WO2008119741A2 (en) * 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
WO2008130614A2 (en) * 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US20090143364A1 (en) * 2004-05-18 2009-06-04 Nader Fotouhi Chiral cis-imidazolines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143364A1 (en) * 2004-05-18 2009-06-04 Nader Fotouhi Chiral cis-imidazolines
US20060293319A1 (en) * 2005-06-24 2006-12-28 Kim-Chun Luk Oxindole derivatives
WO2008119741A2 (en) * 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
WO2008130614A2 (en) * 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists

Also Published As

Publication number Publication date
WO2011106650A2 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
WO2011106650A3 (en) Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
LTC2307454I2 (en) Stable and soluble antibodies that inhibit VEGF
DK2766395T3 (en) ANTIBODY POLYPEPTIDES ANTAGONIZING CD40L
EA201790309A1 (en) ANTIBODIES TO FAP, METHODS OF THEIR RECEPTION AND APPLICATION
CR20130271A (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
EP2308005A4 (en) Temporary domain membership for content sharing
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
DK2563400T3 (en) Modified binding proteins that inhibit VEGF-A receptor interaction
WO2011047087A3 (en) Protein detection via nanoreporters
BRPI1006134A2 (en) antibody or functional antibody fragment, pharmaceutical composition, use of an antibody or functional fragment thereof, polynucleotide, vector, and transformed host cell.
BRPI1014474A2 (en) bispecific antibodies anti-erbb-1 / anti-c-met.
PL2821415T3 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
MX2013005847A (en) Multispecific antigen binding proteins targeting hgf.
MA34025B1 (en) POLYPEPTIDES BINDING TO BETA-A
MX2013010360A (en) Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piper idine-2,6-dione, and their pharmaceutical compositions and uses.
WO2015048484A3 (en) Binding moieties for biofilm remediation
BR112013008255A2 (en) isolated antibody or functional fragment thereof, use of an isolated antibody or functional fragment thereof, pharmaceutical composition, polynucleotide, vector, transformed cell, and method for producing antibody
EA201390254A1 (en) MODIFIED RELAXIN POLYPEPTIDES AND THEIR APPLICATION
EA201500316A1 (en) Antagonists of toll-like receptor 3
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
IL237345A0 (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins, compositions comprising the same and uses thereof
BR112012004304A2 (en) condensed quinolines as protein kinase modulators.
ZA201103588B (en) Polypeptides,antibody variable domains & antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11748150

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11748150

Country of ref document: EP

Kind code of ref document: A2